Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate

Daire O'Shea, John Law, Adrian Egli, Donna Douglas, Gary Lund, Sarah Forester, Joshua D. Lambert, Mansun Law, Dennis R. Burton, D. L.J. Tyrrell, Michael Houghton, Atul Humar, Norman Kneteman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro. Liver Transpl 22:324-332, 2016.

Original languageEnglish (US)
Pages (from-to)324-332
Number of pages9
JournalLiver Transplantation
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Virus Diseases
Neutralizing Antibodies
Hepacivirus
Monoclonal Antibodies
epigallocatechin gallate
Genotype
Liver
Virus Replication
Liver Transplantation
Biological Availability
Antiviral Agents
Vaccines
Cell Culture Techniques

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology
  • Transplantation

Cite this

O'Shea, Daire ; Law, John ; Egli, Adrian ; Douglas, Donna ; Lund, Gary ; Forester, Sarah ; Lambert, Joshua D. ; Law, Mansun ; Burton, Dennis R. ; Tyrrell, D. L.J. ; Houghton, Michael ; Humar, Atul ; Kneteman, Norman. / Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. In: Liver Transplantation. 2016 ; Vol. 22, No. 3. pp. 324-332.
@article{7a1393639e0b44de9462bd1966853bdb,
title = "Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate",
abstract = "The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro. Liver Transpl 22:324-332, 2016.",
author = "Daire O'Shea and John Law and Adrian Egli and Donna Douglas and Gary Lund and Sarah Forester and Lambert, {Joshua D.} and Mansun Law and Burton, {Dennis R.} and Tyrrell, {D. L.J.} and Michael Houghton and Atul Humar and Norman Kneteman",
year = "2016",
month = "3",
day = "1",
doi = "10.1002/lt.24344",
language = "English (US)",
volume = "22",
pages = "324--332",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

O'Shea, D, Law, J, Egli, A, Douglas, D, Lund, G, Forester, S, Lambert, JD, Law, M, Burton, DR, Tyrrell, DLJ, Houghton, M, Humar, A & Kneteman, N 2016, 'Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate', Liver Transplantation, vol. 22, no. 3, pp. 324-332. https://doi.org/10.1002/lt.24344

Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. / O'Shea, Daire; Law, John; Egli, Adrian; Douglas, Donna; Lund, Gary; Forester, Sarah; Lambert, Joshua D.; Law, Mansun; Burton, Dennis R.; Tyrrell, D. L.J.; Houghton, Michael; Humar, Atul; Kneteman, Norman.

In: Liver Transplantation, Vol. 22, No. 3, 01.03.2016, p. 324-332.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate

AU - O'Shea, Daire

AU - Law, John

AU - Egli, Adrian

AU - Douglas, Donna

AU - Lund, Gary

AU - Forester, Sarah

AU - Lambert, Joshua D.

AU - Law, Mansun

AU - Burton, Dennis R.

AU - Tyrrell, D. L.J.

AU - Houghton, Michael

AU - Humar, Atul

AU - Kneteman, Norman

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro. Liver Transpl 22:324-332, 2016.

AB - The anti-hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication. Alone, both exhibit reliable cross-genotype HCV inhibition in vitro, and combination therapy completely prevented HCV infection. In vitro AR4A mAb (alone and combined with EGCG) robustly protects against the establishment of HCV genotype 1a infection. EGCG alone fails to reliably protect against an HCV challenge. In conclusion, AR4A mAb represents a safe and efficacious broadly neutralizing antibody against HCV applicable to strategies to safely prevent HCV reinfection following liver transplantation, and it lends further support to the concept of HCV vaccine development. The poor bioavailability of EGCG limits HCV antiviral activity in vitro. Liver Transpl 22:324-332, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84959549902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959549902&partnerID=8YFLogxK

U2 - 10.1002/lt.24344

DO - 10.1002/lt.24344

M3 - Article

C2 - 26389583

AN - SCOPUS:84959549902

VL - 22

SP - 324

EP - 332

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -